Apellis Pharmaceuticals, Inc. — Director's Dealing 2019

Apr 15, 2019

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Apellis Pharmaceuticals, Inc. (APLS)
CIK: 0001492422
Period of Report: 2019-04-08

Reporting Person: Sadr Ahmad (See Remarks)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right to Buy)	$2.44	2027-02-08	Common Stock (93764)		Direct
Stock Option (Right to Buy)	$14.95	2028-02-16	Common Stock (28750)		Direct
Stock Option (Right to Buy)	$13.85	2029-02-07	Common Stock (45000)		Direct

Footnotes

F1: These options were granted on February 8, 2017 and vested as to 25% of the shares underlying the options on the first anniversary of the grants, with the remaining 75% of the shares underlying the options vesting in equal monthly installments thereafter through the fourth anniversary of the grants, subject to continued service.

F2: These options were granted on February 16, 2018 and vested as to 25% of the shares underlying the options on the first anniversary of the grants, with the remaining 75% of the shares underlying the options vesting in equal monthly installments thereafter through the fourth anniversary of the grants, subject to continued service.

F3: These options were granted on February 8, 2019 and will vest as to 25% of the shares underlying the options on the first anniversary of the grants, with the remaining 75% of the shares underlying the options vesting in equal monthly installments thereafter through the fourth anniversary of the grants, subject to continued service.